The present invention relates to iPSC produced from fibroblast obtained from a subject affected by a neurodevelopmental disorder entailing intellectual disability (ID) and/or a disorder belonging to the Autism Spectrum Disorder (ASD) and/or Schizophrenia (SZ) and uses thereof. The present invention also relates to a cortical neural progenitor cell or a terminally differentiated cortical glutamatergic or gabaergic neuronal cell or a neural crest stem cell line, a mesenchymal stem cell line produced from the iPSC or iPSC line. The invention also relates to method for identifying a compound for the treatment and/or prevention of a neurodevelopmental disorder entailing intellectual disability (ID) and/or a disorder belonging to the Autism Spectrum Disorder (ASD) and/or Schizophrenia (SZ) and to a LSD1 inhibitor or a HDAC2 inhibitor for use in the treatment of such disorders.

Methods are described for using compositions containing platelet-rich plasma for the treatment of a variety of tissue lesions, and the use of compositions containing platelet-rich plasma to accelerate or complete the differentiation of a cell line. Particularly, use of platelet-rich plasma in conjunction with cell differentiation.

Provided is reproducible means that enables the production of an active nucleus pulposus cell phenotype from desired cells such as terminally differentiated cells or pluripotent or multipotent stem cells. Provided is a differentiation inducer containing an effective amount of a gene of at least two transcription factors selected from the group consisting of Brachyury (T), SRY-box6 (SOX6), C and Forkhead Box Q1 (FOXQ1), or homologs thereof (nucleus pulposus cell master regulator transcription factor), or a product thereof.

The present disclosure relates to novel glia-like cells that are differentiated from somatic cells and secrete 20,000 pg/ml or more of HGF, a chemical cocktail composition for producing the same, a method for producing the same, a cell therapy product for treating neurological disorder containing the same, and a method of preventing and treating neurological disorder by administering the same.

Provided are: a composition for inducing direct conversion from somatic cells into common myeloid progenitor cells, the composition including a chemical cocktail; a method of direct conversion of somatic cells into common myeloid progenitor cells and macrophages by using the composition; common myeloid progenitor cells or macrophages prepared by the method; a pharmaceutical composition for preventing or treating fibrosis or scars, cell therapeutics, a composition for screening drugs, and a 3D printable biomaterial composition for fabricating artificial tissues, each using the common myeloid progenitor cells or the macrophages.

The invention provides a method of promoting reprogramming of a cardiac fibroblast into a cardiomyocyte by contacting the cardiac fibroblast with an isolated polynucleotide molecule comprising at least two functional miRNA sequences using a multicistronic expression system for reprogramming of fibroblasts into functional mature cardiomyocytes.

The invention is in the field of cell culturing. More specifically, it is in the field of generating and expanding myogenic cells from induced pluripotent stem (i PS) cells. The invention relates inter alia to cells generated and expanded via such a method, a growth medium specifically suited for the purpose of expanding isolated myogenic cells, and methods for screening compounds on cell structures such as myotubes and myofibers.

The present disclosure relates to compositions, nucleic acid constructs, methods and kits thereof for cell induction or reprogramming cells to the dendritic cell state or antigen presenting cell state, based, in part, on the surprisingly effect described herein of novel use and combinations of transcription factors that permit induction or reprogramming of differentiated or undifferentiated cells into dendritic cells or antigen presenting cells. Such compositions, nucleic acid constructs, methods and kits can be used for inducing dendritic cells in vitro, ex vivo, or in vivo, and these induced dendritic cells or antigen presenting cells can be used for immunotherapy applications.

A method for producing a cell population containing liver progenitor cells, including the steps of

(1) preparing a culture substratum containing a cell population comprising liver progenitor cells and fibroblasts,
(2) physically removing the fibroblast colony from the culture substratum,
(3) detaching cells from the culture substratum, and recovering the detached cells, and
(4) culturing the cells recovered in the step (3) on a collagen-coated culture substratum, and recovering the cells not adhered to the culture substratum is provided by the present invention.

The present invention relates to stem cells derived from a multi-layered cellular structure or blastocyst structure, compositions comprising the same, and methods for obtaining the same.